retatrutide fda approval status 2024 approves this year? Predictions & Odds 2026 Retatrutide vs Survodutide: 24% vs

GLP-1 can act on the central GLP-1 receptors (especially the hypothalamus) and the central satiety center, causing a feeling of satiety and reducing food intake, thus achieving weight loss through appetite suppression

Missing doses can significantly impact your treatment effectiveness, potentially delaying your weight loss results or blood sugar management

You should always seek medical advice from your healthcare provider for any questions or concerns about your medical condition or treatment

Severe nausea, vomiting, and dizziness are less commonly reported with sublingual formulations, though they can still occur, especially at higher doses or when escalating too quickly